Literature DB >> 28957849

Substandard drugs among five common antihypertensive generic medications: an analysis from 10 African countries.

Diane Macquart de Terline1,2,3, Bara I Diop4, Melisande Bernard5,6, Bernard Do5,6, Méo S Ikama7, Roland N'guetta8, Dadhi M Balde9, Yessoufou Tchabi10, Abdallahi Sidi Aly11, Ibrahim Ali Toure12, Patrick Zabsonre13, Jean-Marc F Damorou14, Jean-Laurent Takombe15, Kumar Narayanan16, Christine Fernandez3, Muriel Tafflet1, Pierre-François Plouin1,2,17, Jean-Philippe Empana1, Eloi Marijon1,2,17, Xavier Jouven1,2,17, Marie Antignac1,3.   

Abstract

OBJECTIVE: Hypertension results in more deaths than any other risk factor and has been on the rise in sub-Saharan Africa over the past few decades. Generic drugs have helped improve accessibility and affordability of antihypertensive therapy in developing countries. However, assessment of quality standards of these products is important. We performed a quality assessment of five commonly used antihypertensive generic drugs in 10 sub-Saharan African countries and studied the impact of price on quality.
METHODS: Drug samples were prospectively collected using standardized methods between 2012 and 2014. We developed a validated reversed-phase liquid chromatography with tandem mass spectrometry method to accurately quantify the active ingredient in a certified public laboratory. Quality was defined based on the percentage ratio of measured to expected dosage of active ingredient.
RESULTS: A total of 1185 samples were assessed, of which 70.0% were generic (n = 830). Among the generic drugs, the percentage of poor-quality drugs was 24.3% (n = 202/830). The percentage ratio of measured to expected dosage of active ingredient ranged from 49.2 to 111.3%; the majority (81.7%) of the poor-quality samples had insufficient quantity of the active ingredient. Moreover, poor quality was not associated with purchase price of the drug.
CONCLUSION: In this study from 10 sub-Saharan African countries, nearly one-quarter of the available generic antihypertensive drugs were found to be of poor quality. Concerted measures to improve the quality of antihypertensive drugs could lead to major improvements in hypertension control with attendant reduction of its deleterious consequences in low-income and middle-income countries.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28957849     DOI: 10.1097/HJH.0000000000001560

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

1.  In vitro Comparative Quality Assessment of Different Brands of Furosemide Tablets Marketed in Northwest Ethiopia.

Authors:  Simachew Abebe; Gebremariam Ketema; Haile Kassahun
Journal:  Drug Des Devel Ther       Date:  2020-11-24       Impact factor: 4.162

2.  Post hoc study to investigate the potential causes of poor quality of cardiovascular medicines collected in sub-Saharan countries.

Authors:  Philippe-Henri Secretan; Marie Antignac; Najet Yagoubi; Mélisande Bernard; Marie Cécile Perier; Jean Laurent Takombe; Dadhi Balde; Roland N'Guetta; Méo Stéphane Ikama; Patrice Zabsonre; Abdallahi Sidi Aly; Xavier Jouven; Bernard Do
Journal:  BMJ Open       Date:  2020-11-09       Impact factor: 2.692

Review 3.  A simple six-step guide to National-Scale Hypertension Control Program implementation.

Authors:  Danielle Cazabon; Margaret Farrell; Reena Gupta; Lindsay Joseph; Anupam Khungar Pathni; Swagata Sahoo; Abhishek Kunwar; Kate Elliott; Jennifer Cohn; Thomas R Frieden; Andrew E Moran
Journal:  J Hum Hypertens       Date:  2021-10-26       Impact factor: 2.877

Review 4.  The impact of COVID-19 on patients with neurological disorders and their access to healthcare in Africa: A review of the literature.

Authors:  Olivier Uwishema; Kristian Steen Frederiksen; Inês F Silva Correia; Ashraf Mahmoud; Helen Onyeaka; Burhan Dost
Journal:  Brain Behav       Date:  2022-08-11       Impact factor: 3.405

5.  Falsified and substandard medicines trafficking: A wakeup call for the African continent.

Authors:  Yusuf Hassan Wada; Abdullahi Abdulrahman; Musabu Ibrahim Muhammad; Vivian Chiemerie Owanta; Pearl Udoka Chimelumeze; Garba M Khalid
Journal:  Public Health Pract (Oxf)       Date:  2022-02-26

Review 6.  Pandemics and Burden of Stroke and Epilepsy in Sub-Saharan Africa: Experience from a Longstanding Health Programme.

Authors:  Massimo Leone; Fausto Ciccacci; Stefano Orlando; Sandro Petrolati; Giovanni Guidotti; Noorjehan Abdul Majid; Victor Tamba Tolno; JeanBaptiste Sagno; Darlington Thole; Fabio Massimo Corsi; Michelangelo Bartolo; Maria Cristina Marazzi
Journal:  Int J Environ Res Public Health       Date:  2021-03-09       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.